Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19-SGRP CAR T cells
- Development stage
- Preclinical
- Lead developer
- University of Basel
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-CD19-SGRP CAR T cells are an experimental, engineered adoptive cell therapy designed to treat CD19-positive B-cell malignancies. These CAR T cells are "armored" to constitutively secrete a signal regulatory protein gamma-related protein (SGRP), a high-affinity SIRPγ-derived molecule that binds to CD47 on tumor cells. By blocking the CD47–SIRPα "don't eat me" checkpoint axis in a paracrine manner, the secreted SGRP promotes the phagocytosis of tumor cells by macrophages and microglia within the tumor microenvironment. This dual mechanism—direct T-cell mediated killing via the CD19 CAR and innate immune activation via CD47 blockade—aims to enhance anti-tumor efficacy and overcome resistance mechanisms like antigen escape or immunosuppression. The therapy has demonstrated superior efficacy in preclinical mouse models of CD19+ lymphoma compared to conventional anti-CD19 CAR T cells.
- Other names
- anti-CD19-SGRP CAR Tanti-CD-19-SGRP CAR Tanti-CD 19-SGRP CAR TSGRP-armored anti-CD19 CAR T cells
02
Targets
CD19 (B lymphocyte antigen CD19)CD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on anti-CD19-SGRP CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19-SGRP CAR T cells.